Clinical trial
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal…
NCT00331864 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00331864 |
|---|---|
| Title | SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration |
| Official title | A Phase IIIb, Open-label, Multi-center 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of Ranibizumab (0.3 mg and/or 0.5 mg) in Patients With Subfoveal Choroidal Neovasculariza-tion Secondary to Age-related Macular Degeneration |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Age Related Macular Degeneration, Choroidal Neovascularization |
| Intervention type | Drug |
| Interventions | Ranibizumab |
| Enrollment | 531 |
| Start date | Apr 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | May 31, 2006 |
| Last update posted | Feb 18, 2011 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: